SCHEMBL15925815

SCHEMBL15925815

Clc1cc(N2CCC2)cc2c1Nc1c(Cl)cc(N3CCC3)cc1S2

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 6/20 0.37
CHRNA4 P43681 6/20 0.37
IP6K1 Q92551 1/20 0.36
ADRB1 P08588 2/20 0.35
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
CHRNA1 P02708 1/20 0.33
CHRNA7 P36544 1/20 0.33
MAPT P10636 2/20 0.32
ALDH1A1 P00352 2/20 0.32
GFER P55789 1/20 0.32
LMNA P02545 2/20 0.31
ALOX12 P18054 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15925813 0.97 IP6K1 (0.39) CHRNB2CHRNA4IP6K1ADRB1CHRM2
SCHEMBL15875883 0.89 CHRNB2 (0.48) CHRNB2CHRNA4ADRB1CHRM2CHRM4
SCHEMBL15875881 0.87 ADRB1 (0.51) CHRNB2CHRNA4ADRB1CHRM2CHRM4
SCHEMBL15948157 0.77 SLC29A1 (0.34) CHRNB2CHRNA4
SCHEMBL12273209 0.74 IP6K1 (0.34) IP6K1
SCHEMBL13386335 0.72 MAPT (0.43) MAPTALDH1A1LMNASMN1; SMN2HTT
SCHEMBL13386162 0.69 MAPT (0.44) MAPTALDH1A1LMNAALOX12SMN1; SMN2
Iodide SCHEMBL13386326 0.68 MAPT (0.44) MAPTALDH1A1LMNAALOX12SMN1; SMN2
SCHEMBL17896427 0.68 MAPT (0.42) MAPTALDH1A1LMNASMN1; SMN2HTT
SCHEMBL15909170 0.68 SNCA (0.42) MAPTALDH1A1LMNAALOX12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 US disclosed
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease PSEN1, APP, PSEN2 CHRNB2 725/4885CHRNA4 443/4885IP6K1 1490/4885
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 CHRNB2 725/4885CHRNA4 443/4885IP6K1 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.